Bellicum Receives FDA IND Clearance to Initiate a Phase 1/2 Clinical Trial for BPX-603, a Dual-Switch GoCAR-T® for HER2+ Solid Tumors
15 juin 2020 07h30 HE
|
Bellicum Pharmaceuticals, Inc.
HOUSTON, June 15, 2020 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced clearance by...
Bellicum Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
29 mai 2020 16h06 HE
|
Bellicum Pharmaceuticals, Inc.
HOUSTON, May 29, 2020 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced equity...
Bellicum Announces Publication of Data for GoCAR-NK™ Cell Program
27 mai 2020 16h05 HE
|
Bellicum Pharmaceuticals, Inc.
HOUSTON, May 27, 2020 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced the...
Bellicum to Participate in Two Upcoming Virtual Investor Conferences
27 mai 2020 07h30 HE
|
Bellicum Pharmaceuticals, Inc.
HOUSTON, May 27, 2020 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that...
Bellicum Reports First Quarter 2020 Financial Results and Provides Operational Update
07 mai 2020 16h05 HE
|
Bellicum Pharmaceuticals, Inc.
Bellicum’s three GoCAR™ programs remain on track Completed $15 million sale of manufacturing, office and laboratory facility to MD Anderson and entered into supply agreement HOUSTON, May 07, 2020 ...
Bellicum Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
30 avr. 2020 16h09 HE
|
Bellicum Pharmaceuticals, Inc.
HOUSTON, April 30, 2020 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced equity...
Bellicum Completes Sale of Houston Facility
15 avr. 2020 07h30 HE
|
Bellicum Pharmaceuticals, Inc.
Purchase price of $15 million from sale of manufacturing, office and laboratory facility Current and future GoCAR™ product candidates to be manufactured by MD Anderson HOUSTON, April 15, 2020 ...
Bellicum Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Operational Update
12 mars 2020 16h05 HE
|
Bellicum Pharmaceuticals, Inc.
Presented new Phase 1 translational results for BPX-601 at ASCO GI Initiated new GoCAR-NK™ program targeting BCMA Entered into asset purchase agreement and licensed technology to MD Anderson ...
Bellicum to Report Fourth Quarter and Full Year 2019 Financial Results and Provide Corporate Update
05 mars 2020 07h30 HE
|
Bellicum Pharmaceuticals, Inc.
HOUSTON, March 05, 2020 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced it will...
Bellicum Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
28 févr. 2020 16h08 HE
|
Bellicum Pharmaceuticals, Inc.
HOUSTON, Feb. 28, 2020 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced equity...